Abstract
Bleomycins are a family of compounds produced byStreptomyces verticillis. They have potent tumour killing properties which have given them an important place in cancer chemotherapy. They cause little marrow suppression, but pulmonary toxicity is a major adverse effect. The mechanisms of cell toxicity are well described based on in vitro experiments on DNA. The bleomycin molecule has two main structural components; a bithiazole component which partially intercalates into the DNA helix, parting the strands, as well as pyrimidine and imidazole structures, which bind iron and oxygen forming an activated complex capable of releasing damaging oxidants in close proximity to the polynucleotide chains of DNA. This may lead to chain scission or structural modifications leading to release of free bases or their propenal derivatives. The mechanisms are well described based on in vitro experiments on DNA, but how they relate to intact cells in whole animals is more tenuous. Bleomycin is able to cause cell damage independent from its effect on DNA by inducing lipid peroxidation. This may be particularly important in the lung and in part account for its ability to cause alveolar cell damage and subsequent pulmonary inflammation. The lung injury seen following bleomycin comprises an interstitial oedema with an influx of inflammatory and immune cells. This may lead to the development of pulmonary fibrosis, characterized by enhanced production and deposition of collagen and other matrix components. Several polypeptide mediators capable of stimulating fibroblasts replication or excessive collagen deposition have been implicated in this, but the precise role of these in bleomycin-induced fibrosis is yet to be demonstrated. Current therapy for bleomycin-induced lung damage is inadequate, with corticosteroids most often used. Given the mechanism of action described above, antioxidants and iron chelators might be beneficial. Although, studies to date are equivocal and there is insufficient evidence to promote their use clinically. Novel drugs are currently being developed and it is hoped these may be more useful.
Similar content being viewed by others
References
Adamson IYR, Bowden DH (1979) Bleomycin-induced injury and metaplasia of alveolar type 2 cells. Am J Pathol 96: 531–538
Agostini MJ, Bernacki RJ, Beerman TA (1984) Synergistic interactions of ethidium bromide and bleomycin on cellular DNA and growth inhibition. Biochem Biophys Res Commun 120: 156–163
Albertini JP, Garnier-Suillerot A (1984) Iron-bleomycin-deoxyribonucleic acid system. Evidence of DNA interaction with the α-amino group of the aminoalanine moiety. Biochemistry 23: 47–53
Alberts DS, Chen H-SG, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, Gross J, Moon T, Broughton A, Salmon SE (1978) Bleomycin pharmacokinetics in man. Cancer Chemother Pharmacol 1: 177–181
Antholine WE, Hyde JS, Sealy RC, Petering DH (1984) Structure of cupric bleomycin. J Biol Chem 259: 4437–4440
Antonelli G, Dianzani F, Damme JV, Amicucci P, Marco FD, Gefaro A (1988) A macrophage-derived factor different from interleukin-1 and able to induce interferon- and lymphoproliferation in resting T lymphocytes. Cell Immunol 113: 376–386
Assoian RK, Grotendorst GR, Miller DM, Sporn MB (1984) Cellular transformation by coordinated action of three peptide growth factors from human platelets. Nature (Lond) 309: 804–806
Baggiolini MJ, Schnyder J, Bretz U, Dewald B, Ruch W (1980) Cellular mechanisms of proteinase release from inflammatory cells and the degradation of extracellular proteins. In: Protein degradation in health and disease. Ciba Foundation Symposium 75, Excerpta Medica, New York, pp 105–118
Baird A, Durkin T (1986) Inhibition of endothelial cell proliferation by TGFβ: Interaction with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun 138: 476–482
Barlogie B, Drewinko B, Schumann J, Freireich EJ (1976) Pulse cytopotometric analysis of cell pertubation with bleomycin in vitro. Cancer Res 31: 1182–1187
Barranco SC, Luce JK, Romsdahl MM, Humphrey RM (1973) Bleomycin as a possible synchronising agent for human tumour cell in vivo. Cancer Res 33: 882–887
Bauer KA, Skarin AT, Balikian JP, Garnick MB, Rosenthal DS, Canellos GP (1983) Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med 74: 557–763
Bedrossian CWM, Luna MA, Mackay B, Lichtiger B (1973) Ultrastructure of pulmonary bleomycin toxicity. Cancer 32: 44–51
Bellamy EA, Husband JE, Blaquiere RM, Law MR (1985) Bleomycin related lung damage: CT evidence. Radiology 156: 155–158
Bennett JM, Reich SD (1979) Drugs five years later. Bleomycin. Ann Int Med 90: 945–948
Bernier J, Kenani A, Houssin R, Helbecque N, Lohez M, Heoquet B, Henichart J (1986) Molecular interactions between bleomycin and amsacrine in the presence of cupric ions. J Inorg Biochem 27: 271–285
Berry DE, Chang L, Hecht SM (1985a) DNA damage and growth inhibition in cultured human cells by bleomycin congeners. Biochemistry 24: 3207–3213
Berry DE, Kilkuskie RE, Hecht SM (1986b) DNA damage induced by bleomycin in the presence of dibucaine is not predictive of cell growth inhibition. Biochemistry 24: 3214–3219
Blum RH et al. (1973) A clinical review of bleomycin. Cancer 31: 903–914
Broughton A, Strong J (1976) Radioimmunoassay of bleomycin. Cancer Res 35: 1418–1421
Burger RM, Peisach J, Blumberg WE, Horwitz SB (1979) Iron-bleomycin interactions with oxygen and oxygen analogues. J Biol Chem 21: 10906–10912
Burger RM, Peisach J, Horwitz SB (1981) Activated bleomycin. A transient complex of drug, iron and oxygen that degrades DNA. J Biol Chem 256: 11636–11644
Burger RM, Peisach J, Horwitz SB (1982) Stoichiometry of DNA strand scission and aldehyde formation by bleomycin. J Biol Chem 257: 8612–8614
Burger RM, Freedman JH, Horwitz SB, Peisach J (1984) DNA degradation of manganese (II)-bleomycin plus peroxide. Inorg Chem 23: 2215–2217
Burger RM, Blanchard JS, Horwitz SB, Peisach J (1985) The redox state of activated bleomycin. J Biol Chem 260: 15406–15409
Catane R, Schwade JG, Turisi AT, Webbe BC, Muggin FM (1979) Pulmonary toxicity after irradiation and bleomycin. Int J Radiat Oncol Biol Phys 1513–1518
Chandler DB, Hyde DM, Giri SN (1983) Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am J Pathol 112: 170–177
Chandler DB, Fulmer JD (1985) The effect of deferoxamine on bleomycin-induced lung fibrosis in the hamster. Am Rev Respir Dis 131: 596–598
Chang CH, Meares CF (1984) Cobalt-bleomycins and deoxyribonucleic acid: Sequence dependent interactions, action spectrum for nicking, and indifference to oxygen. Biochemistry 23: 2268–2274
Clark JG, Overton JE, Marino BA, Uitto J, Starcher BC (1980) Collagen biosynthesis in bleomycin-induced pulmonary fibrosis in hamsters. J Lab Clin Med 96: 943–953
Collis CH (1980) Lung damage from cytotoxic drugs. Cancer Chemother Pharmacol 4: 17–27
Comis RL (1978) Bleomycin pulmonary toxicity. In: Carter SK, Umezawa H, Crooke ST (eds) Bleomycin status and new developments. Academic Press, New York, pp 279–291
Cooper KR, Hong WK (1981) Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep 65: 419–425
Crapo JD, Tierney DF (1974) Superoxide dismutase and oxygen toxicity. Am J Physiol 226: 1401–1407
Crooke ST, Einhorn LH, D'Aoust JC, Prestayko AW (1978) The effects of prior exposure to bleomycin on the incidence of pulmonary toxicities in a group of patients with disseminated testicular carcinomas. Med Pediatr Oncol 5: 93–98
Cross CE, Warren D, Gerriets JE, Wilson DW, Halliwell B, Last JA (1985) Desferrioxamine injection does not affect bleomycin-induced lung fibrosis in rats. J Lab Clin Invest 106: 433–438
Dalgleish AG, Woods RL, Levi JA (1984) Bleomycin pulmonary toxicity; its relationship to renal mysfunction. Med Pediatr Oncol 12: 313–317
Dayer JM, Passwell HJ, Schneeberger EE, Krane SM (1980) Intercutions among rheumatoid synovial cells and monocyte-macrophages: production of collagenase-stimulating factor by human monocytes exposed to concanavalin A or immunoglobulin Fc fragments. J Immunol 124: 1712–1720
Dayer JM, Beutler B, Cerami A (1985) Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163–2168
DeLena M, Guzzon A, Monfardini S, Bonadonna G (1972) Clinical, radiologic and histopathologic studies on pulmonary toxicity induced by treatment with bleomycin. Cancer Chemother Rep 56: 343–355
De-Petro G, Barlati S, Vartio T, Vaheri A (1983) Transformation-enhancing activity in plasma of tumour patients: Relationship with fibronectis fragments. Int J Cancer 31(2): 157–162
DiCorleto PE (1984) Cultured endothelial cells produce multiple growth factors for connective tissue cells. Exp Cell Res 153: 167–172
Dingle JT, Saklatvala J, Hembry R, Tyler J, Fell HB, Jubb R (1979) A cartilage catabolic factor from synovium. Biochem J 184: 177–180
Ehrenfeld GM, Murugesan N, Hecht SM (1984) Activation of oxygen and mediation of DNA degradation by manganese-bleomycin. Inorg Chem 23: 1496–1498
Ehrenfeld GM, Rodriguez LO, Hecht SM, Chang C, Basus VJ, Oppenheimer J (1985) Copper(I)-bleomycin: Structurally unique complex that mediates oxidative DNA strand scission. Biochemistry 24: 81–92
Einhorn L, Krause M, Hornback N, Furnas B (1976) Enchanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer 37: 2414–2416
Ekimoto H, Takahashi K, Matsuda A, Takita T, Umezawa H (1985) Lipid peroxidation by bleomycin-rion complexes in vitro. J Antibiot 38: 1077–1082
Fisher LM, Kuroda R, Sakai TT (1985) Interaction of bleomycin A2 with deoxyribonucleic acid: DNA unwinding and inhibition of bleomycin induced DNA breakage by cationic thiazol amides related to bleomycin A2. Biochemistry 24: 3199–3207
Frater-Schroder M, Miller G, Birchmeier W, Bohleu P (1986) TGFβ inhibits endothelial cell proliferation. Biochem Biophys Res Commun 137: 295–302
Giloni L, Takeshita M, Johnson F, Iden C, Grollman AP (1981) Bleomycin induced strand scission of DNA. Mechanism of deoxyribose cleavage. J Biol Chem 256: 8608–8615
Ginsberg SJ, Comis RL (1982) The pulmonary toxicity of antineoplastic agents. Semin Oncol 9: 34–51
Giri SN (1986) Pharmacokinetics, subcellular distribution and covalent binding of [3H] bleomycin in hamsters after intratracheal administration. Exp Mol Pathol 45: 207–220
Giri SN, Schwartz LW, Hollinger MA, Freywald MF, Schiedt MJ, Zuckerman JE (1980) Biochemical and structural alterations of hamster lungs in response to intratracheal administration of bleomycin. Exp Mol Pathol 33: 1–14
Goldstein RH, Lucey EC, Franzblau C, Snider GL (1979) Failure of mechanical properties of parallel changes in lung connective tissue composition in bleomycin-induced pulmonary fibrosis in hamsters. Am Rev Respir Dis 120: 67–73
Goldiner PL, Carlon GC, Cvitovic E, Schweizer O, Howland WS (1978) Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1: 1664–1667
Gray AJ, Reeves JT, Harrison NK, Winlove P, Laurent GJ (1990) Growth factors for human fibroblasts in the solute remaining after clot formation. J Cell Sci (in press)
Grotendorst GR (1984) Alteration of the chemotactic response of NIH/3T3 cells of PDGF by growth factors, transformation and tumor promoters. Cell 36: 279–285
Grotendorst GR, Seppa HEJ, Kleinman HK, Martin GR (1981) Attachment of smooth muscle cells of collagen and their migration toward platelet-derived growth factor. Proc Natl Acad Sci 78: 3669–3672
Gutteridge JMC, Richmond R, Halliwell B (1979) Inhibition of iron-catalysed formation of hydroxyl radicals from Superoxide and lipid peroxidation by desferioxamine. Biochem J 184: 469–472
Haas CD, Coltman CA, Gottlieb JA, Haut A, Luce JK, Talley RW, Samal B, Wilson HE (1976) Phase II evaluation of bleomycin. Cancer 38: 8–12
Halliwell B (1985) Use of desferrioxamine as a probe for iron-dependent formation of hydroxyl radicals. Evidence for a direct reaction between Desferal and the Superoxide radical. Biochem Pharmacol 1985; 34: 229–233
Hay JG, Haslam PL, Dewer A, Addis B, Laurent GJ (1987a) The development of acute lung injury following the combination of intravenous bleomycin and exposure to hyperoxia in rats. Thorax 42: 374–382
Hay JG, Haslam PL, Staple LH, Laurent GJ (1987 b) Role of iron and oxygen in bleomycin-induced pulmonary edema. In: Alturaa BM, Davis E (eds) Advances in microcirculation 13: 239–255
Hay JG, Haslam PL, Turner-Warwick M, Laurent GJ (1987c) The effect of iron and desferrioxamine on the lung injury induced by intravenous bleomycin and hyperoxia. Free Rad Res Commun 4: 109–114
Hecht SM (1986) DNA strand scission by activated bleomycin group antibiotics. Fed Proc 45: 2784–2791
Henichart JP, Bernier JL, Lemay P, Houssin R, Catteau JP (1984) Subcellular distribution of spin-labelled bithiazoles and bleomycin in living KB cells: an ESR study, Cancer Biochem Biophys 7: 239–244
Hewitt SD, Hider RC, Serpong P, Morris CJ, Blake DR (1989) Investigation of the anti-inflammatory properties of hydroxypyridones. Ann Rheum Dis 48: 383–388
Hider RC (1984) Siderophore mediated absorption of iron. Struct Bond 58: 25–87
Holoye PY, Luna MA, MacKay B, Bedrossian CWM (1978) Bleomycin hypersensitivity pneumonitis. Ann Int Med 88: 47–49
Hou D, Hoch H, Johnston GJ, Tsou KC, Farkas RJ, Miller EE (1984) Distribution and stability of [111In] bleomycin and its fractions in tumour-bearing mice. Int J Nucl Med Biol 11: 129–139
Iacovino JR, Leitner J, Abbas AK, Lokich JJ, Snider GL (1976) Fatal pulmonary reaction from low does of bleomycin. JAMA 235: 1253–1255
Itaka Y, Nakamura H, Nakatani T, Muraoka Y, Fujii A, Takita T, Umezawa H (1978) Chemistry of bleomycin. The X-ray structure determination of P3A Cu(II) complex. J Antibiot 31: 1070–1072
James H, Harrison JR, Lazo JS (1987) High dose continuous infusion of bleomycin in mice: A new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 243(3): 1185–1194
Jamieson DD, Kerr DR, Unsworth I (1987) Interaction of N-acetyl cysteine and bleomycin on hyperbaric oxygen-induced lung damage in mice. Lung 165[4]: 239–247
Jimenez SA, Freundlich B, Rosenbloom J (1984) Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 74[3]: 1112–1116
Joelson R, Warnock M (1983) Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol 13: 88–91
Jones AW (1978) Bleomycin lung damage: the pathology and nature of the lesion. Br J Dis Chest 72: 321–326
Kanofsky JR (1986) Singlet oxygen production by bleomycin. J Biol Chem 261: 13546–13550
Kappus H, Mahmutoglu I (1986) Oxygen radical formation during redox cycling of bleomycin-Fe(III) catalyzed by NADPH-cytochrome P-450 reductase of liver microsomes and nuclei. Adv Exp Med Biol 197: 273–280
Karlinsky JB (1982) Glycosaminoglucans in emphysematous and fibrotic hamster lungs. Am Rev Respir Dis 125: 85–88
Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS (1986a) Production of TGFβ by human T-lymphocyte and its potential role in the regulation of T-cell growth. J Exp Med 163: 1037–1050
Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS (1986b) Transforming growth factor β is an important immunomodullatory protein for human B lymphocytes. J Immunol 137: 3855–3860
Kempf RA, Mitchell MS (1985) Effects of chemotherapeutic agents on the immune response. Cancer Invest 3: 23–33
Khalil N, Bereznay O, Sporn M, Greenberg AH (1989) Macrophage production of TGFβ and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med 170: 727–737
Khansur T, Little D, Tavassoli M (1984) Fulminant and fatal angiodema caused by bleomycin treatment. Arch Int Med 144: 2267
Koenig WJ, Cross CE, Hesterberg TW, Last JA (1983) Mechanism of methylprednisolone prevention of bleomycin induced pulmonary fibrosis. Chest 5: 5S-7S
Krakoff IH, Cvitkovic E, Currie V, Yeh S, Lamont C (1977) Clinical Pharmacology and therapeutic studies of bleomycin given by continuous infusion. Cancer 40: 2027
Kuwahara J, Suzuki T, Sugiura Y (1985) Effective DNA cleavage by bleomycin-vanadium complex plus hydrogen peroxide. Biochem Biophys Res Comm 129: 368–374
Laurent GJ (1986) Lung collagen: more than Scaffolding. Thorax 41: 418–428
Laurent GJ, McAnulty RJ (1983) Protein metabolism during bleomycin-induced pulmonary fibrosis in rabbits. Am Rev Respir Dis 128: 82–88
Laurent GJ, McAnulty RJ, Corrin B, Cockerill P (1981) Biochemical and histological changes in pulmonary fibrosis induced in rabbits with intratracheal bleomycin. Eur J Clin Invest 11: 441–448
Laurent GJ, Bishop JE, Gray A, Peacock A, Harrison NK, Winlove CP, Lever MJ, Reeves JT (1990) Deposition of arterial collagen in pulmonary hypertension. Putative role for growth factors derived from the circulation. In: Herget J, Widimsky J (eds) Progress in respiration research. Basel-Karger, Switzerland (in press)
Lazo JS, Pham ET (1984) Pulmonary fate of [3H] bleomycin A2 in mice. J Pharmacol Exp Ther 228: 13–18
Lazo JS, Humphreys CJ (1983) Lack of metabolism as the biochemical basis of bleomycin induced pulmonary toxicity. Proc Natl Acad Sci USA 80: 3064–3068
Lazo JS, Merril WW, Pham ET, Lynch TJ, McCallister JD, Ingbar DH (1984) Bleomycin hydrolase activity in pulmonary cells. J Pharmacol Exp Ther 231: 583–588
Lazo JS, Braun IB, Meandzija B, Kennedy KA, Pham ET, Smaldone LF (1985) Lidocaine potentiation of bleomycin cytotoxicity and DNA strand breakage in L1210 and human A-253 cells. Cancer Res 45: 2103–2109
Levy RL, Chiarillo S (1980) Hyperpyrexia, allergic type reaction and death occurring with low dose bleomycin administration. Oncology 37: 316–317
Lijnen HR, Collen D (1982) Interaction of plasminogen activators and inhibitors with plasminogen and fibrosis. Semin Thromb Hemost 8: 2–10
Lown JW, Sondhi SM, Ong C, Skorobogaty A, Kishikawa H, Dabrowiak JC (1986) Deoxyribonucleic acid cleavage specificity of a series of acridine and acodazole iron porphyrins as functional bleomycin models. Biochemistry 25: 5111–5117
Luna MA, Bedrossian CWM, Lichtiger B, Salem PA (1972) Interstitial pneumonitis associated with bleomycin therapy. AJCP 58: 501–510
Lyman S, Ujjani B, Renner K, Antholine W, Pertering DH, Whetstone JW, Knight JM (1986) Properties of the initial reaction of bleomycin and several of its metal complexes with Ehrlich cells. Cancer Res 46: 4472–4478
Martinet Y, Bitterman PB, Mornex J-F, Grotendorst GR, Martin GR, Crystal RG (1986) Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature (Lond) 319: 158–160
Masui T, Wakefield LM, Lechner JF, Laveek MA, Sporn MB, Harris CC (1986) TGFβ is the primary differentation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Acad Sci USA 83: 2438–2442
Matalon S, Harper WV, Goldinger JM, Nickerson PA, Olszowka J (1985) Modification of pulmonary oxygen toxicity by bleomycin treatment. J Appl Physiol 58: 1802–1809
Mauviel A, Daireaux M, Redini F, Galera P, Loyau G, Pujol JP (1988) Tumor necrosis factor inhibits collagen and fibronecting synthesis in human derraml fibroblasts. FEBS Letts 236: 47–52
McCord JM, Fridovich I (1969) Superoxide dismutase. J Biol Chem 244: 6049–6055
McCullough B, Collins JF, Grover FL (1978) Bleomycin-induced diffuse interstitial pulmonary fibrosis in baboons. J Clin Invest 61: 79–88
Meikle MC, Heath JK, Reynolds JJ (1986) Advances in understanding cell interactions in tissue resorption. Relevance to the pathogenesis of periodontal diseases and a new hypothesis. J Oral Pathol 15: 239–250
Metcalfe DD, Smith JA, Austen KF, Silbert JE (1980) Polydispersity of rat mast cell heparin. Implication for proteoglycan assembly. J Biol Chem 25[255]: 11753–11758
Mirabelli CA, Ting A, Huang CH, Mong S, Crooke ST (1982) Bleomycin and talisomycin sequence specific strand scission of DNA: a mechanism of double strand cleavage. Cancer Res 42: 2779–2785
Mizel SB, Dayer JM, Krane SM, Mergenhagen E (1981) Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin-1). Proc Nat Acad Sci USA 78: 2472–2477
Mizuno S, Ishida A (1982) Selective enhancement of bleomycin cytotoxicity in local anaesthetics. Biochem Biophys Res Commun 105: 425–431
Mizuno S, Ishida A (1982) Potentiation of bleomycin cytotoxicity by membrane acting drugs and increased calcium ions. Biochem Biophys Res Commun 107: 1021–1027
Moses HL, Tucker RF, Leof EB, Coffey RJ, Halper J, Shipley GD (1985) Type beta transforming growth factor is a growth stimulator and a growth inhibitor in cancer cells. In: Feramisco J, Ozanne B, Stiles C (eds) Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp 65–71
Moshere DF (1975) Cross-linking of cold-soluble globulin by fibrin-stabilizing factor. J Biol Chem 16: 6614–6612
Muller WEG, Zahn RK, Maidhof A, Schroder HC, Bachman M, Umezawa H (1984) Synergistic effect of peplomycin in combination with bleomycin on L5178y mouse lymphoma cells in vivo. J Antibiot 37: 239–243
Murphy G, Sellars A (1980) The extracellular regulation of collagen activity. In: Woolley DE, Evanson JM (eds) Collagenase in normal and pathological connective tissues. John Wiley and Sons, Chichester, England, pp 65–81
Nagase H, Jackson RC, Brinckerhoff CE, Vater CA, Harris ED Jr (1981) A precursor form of latent collagenase produced in a cell-free system with mRNA from rabbit synovial cells. J Biol Chem 256: 11951–11954
Norris DA, Clark RAF, Swigart LM, Huff JC, Clark J, Weston WL, Howell SE (1982) Fibronectin fragment(s) are chemotactic for human peripheral blood monocytes. J Immunol 129: 1612–1618
Nugent KM, Glazier J, Monick MM, Hunninghake GW (1985) Stimulated human alveolar macrophages secrete interferon. Am Rev Respir Dis 131[5]: 714–718
Nygard K, Smith-Erichsen N, Hatlevoll R, Refsum SB (1978) Pulmonary complications after bleomycin, irradiation and surgery for oesophageal cancer. Cancer 41: 17
Oberley LW, Buettner GR (1979) The production of hydroxyl radical by bleomycin and iron(II). FEBS Lett 97: 47–49
Ohnuma T, Holland JF, Masuda H, Waligunda JA, Goldberg GA (1974) Microbiological assay of bleomycin: inactivation, tissue distribution and clearance. Cancer 33: 1230–1238
Oppenheimer NJ, Rodriguez LO, Hecht SM (1979) Structural studies of the active complex of bleomycin. Proc Natl Acad Sci USA 76: 5616–5620
Oppenheimer NJ, Chang C, Chang LH, Ehrenfeld G, Rodriguez LO, Hecht SM (1982) Degradation of DNA and formation of a structurally unique Fe(II) CO complex. J Biol Chem 257: 1606–1609
Padmanabhan RV, Gudapaty R, Liener IE, Schwartz BA, Hoidal JR (1985) Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome encapsulated Superoxide dismutase or catalase. Am Rev Respir Dis 132: 164–167
Pearlstein E (1976) Plasma membrane glucoprotein which mediates adhesion of fibroblasts to collagen. Nature (Lond) 262: 497–499
Peng YM, Alberts DS, Chen HSG, Mason N, Moon TE (1980) Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. Br J Cancer 41: 644–647
Phan SH, Thrall RS, Williams C (1981) Bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis 124: 428–434
Postlethwaite AE, Keski-Oja J, Balian G, Kang AH (1981) Induction of fibroblast chemotaxis by fibronectin. J Exp Med 153: 494–499
Prestayko AW, Crooke ST (1978) Clinical pharmacology of bleomycin. In: Carter SK, Umezawa H, Crooke ST (eds) Bleomycin: Current status and new developments. Academic Press Inc New York, 117–130
Reich E (1978) Activation of plasminogens: a general mechanism for producing localized extracellular proteolysis. In: Berlin RD, Herrman H, LePow IH, Tanzer JM (eds) Molecular basis of biological degradative processes. Academic Press, London, pp 155–170
Reiser KM, Last JA (1981) Pulmonary fibrosis in experimental acute respiratory disease. Am Rev Respir Dis 123: 58–63
Rifkin DB, Moscatelli D, Gross J, Jaffe EA (1984) Proteases, angiogenesis and invasion. In: Nicolson GL, Milas L (eds) Cancer invasion and metastasis: biologic and therapeutic aspects. Raven Press, New York, pp 187–200
Riordan JW, Sakai TT (1983) Bleomycin analogues. Phenylthiazole models of the bithiazole moiety of bleomycin A2. J Med Chem 26: 884–891
Roll W, Sherry S, Wachman J (1954) The action of plasmin on synthetic pulstrates. J Biol Chem 208: 85
Rose AG (1983) Pulmonary veno-occlusive disease due to bleomycin therapy for lymphoma. S Afr Med J 64: 636–638
Rosenbaum RM, Wittner M, Lenger M (1969) Mitochondrial and other ultrastructural changes in great alveolar cells of oxygen-adapted and poisoned rats. Lab Invest 20: 516–528
Rossi P, Karsenty G, Roberts AB, Roche NS, Sporn MB, de Crombrugghe B (1988) A nuclear factor 1 binding site mediated the Transcriptional activation of a type I collagen promoter by TGFβ. Cell 52[3]: 405–414
Roy SN, Horwitz SB (1984) Characterisation of the association of radiolabelled BLM A2 with Hela cells. Cancer Res 44: 1541–1546
Sakamoto S, Sakamoto M (1981) Effect of heparine on bone collagenase release and activity and an application of heparin-Sepharose affinity chromatography for in vitro study of bone resorption. In: Brown WV, Mann G, Roberts R, Lundblad L (eds) The chemistry and biology of heparin. Churchill Livingstone, London, pp 362–375
Samuels ML, Lanzotti VJ, Holoyle PY, Boyce LE, Smith TL (1976) Combination chemotherapy in terminal tumours. Cancer Treat Rev 3: 185
Sartoris DJ, Goodwin DA, Meares CF, DeRiemer LH, Fajardo LF (1984) Pharmacokinetics of indium-111 BLEDTA in man. Invest Radiol 19: 221–227
Saus J, Quinones S, Otani Y, Nagase H, Harris JR, Kurkineu M (1988) The complete primary structure of human matrix metalloproteinase-3. J Biol Chem 263: 6742–6745
Sausville EA, Peisach J, Horwitz SB (1976) A role for ferrous iron and oxygen in the degradation of DNA by bleomycin. Biochem Biophys Res Commun 73: 814–822
Sausville EA, Peisach J, Horwitz SB (1978) Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry 17: 2740–2745
Scheid W, Opperman B, Traut H (1984) The cytogenetic efficiency of the antitumour agents bleomycin and peplomycin is enhanced by the heart drug verapamil. Experientia 40: 746–747
Scheulen MD, Kapus H, Thyssen D, Schmidt CG (1981) Reduction cycling of Fe(III)-bleomycin by NADPH-cytochrome P-450 reductase. Biochem Pharmacol 30: 3385–3388
Seki T, Muraoka Y, Takahashi K, Horinishi H, Umezawa H (1985) Radioimmunoassays of bleomycin. J Antibiot 38: 1251–1256
Sen P, Hittleman WN (1984) Kinetics and extent of repair of bleomycin induced chromosome damage in quiescent normal human fibroblasts and human mononuclear cells. Cancer Res 44: 591–596
Seppa H, Grotendorst G, Seppa S, Schiffmann E, Martin GR (1982) Platelet-derived growth factor is chemotactic for fibroblasts. J Cell Biol 92[2]: 584–588
Stubbe J, Kozarich JW (1987) Mechanisms of bleomycin induced DNA degradation. Chem Rev 87: 1107–1136
Shazeidi S, Sarnstrand B, Jeffery PK, McAnulty RJ, Laurent GJ (1991) Oral N-acetylcysteine reduced bleomycin-induced collagen deposition in the lungs of mice. Eur Respir J (in press)
Shipley GD, Pittelkow ME, Wille JJ, Scott RE, Moses HL (1986) Reversible inhibition of normal human prokerationcyte proliferation by TGFβ-growth inhibitor in serum free medium. Cancer Res 46: 2064–2071
Snider GL, Hayes JA, Kortly AL (1978) Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin: Pathology and Stereology. Am Rev Respir Dis 117: 1099–1108
Sporn ME, Roberts AB, Anzanmo A, Wakefield LM, Roche NS, Stern DF (1985) Type β transforming growth factor β1 functional regulator of cellular growth. Proc Natl Acad Sci USA 82: 119–123
Starcher BC, Kuhn C, Oerton JE (1978) Increased elastin and collagen content in the lungs of hamsters receiving an intratracheal injection of bleomycin. Am Rev Respir Dis 117: 299–305
Sterling KM, DiPetrillo T, Cutoneo KC, Prestayko A (1982) Inhibition of collagen accumulation by glucocorticoids in rat lung after intratracheal bleomycin instillation. Cancer Res 42: 405–408
Sugiura Y (1980) Bleomycin iron complexes. ESR study ligand effect, and implications for action mechanisms. J Am Chem Soc 102: 5208–5216
Sugiura Y, Suzuki T, Otuska M, Kobayashi S, Ohno M, Takita T, Umezawa H (1983) Synthetic analogues and biosynthetic intermediates of bleomycin. J Biol Chem 258: 1328–1336
Suzuki H, Nagai K, Yamaki H, Umezawa H (1969) On the mechanism of action of bleomycin scission of DNA strand in vitro and in vivo. J Antibiot 22: 446–448
Suzuki T, Kuwahara J, Sugiura Y (1984) DNA cleavages of bleomycin transition metal complexes induced by reductant, hydrogen peroxide and ultraviolet light. Nucleic Acids Res 15: 161–164
Suzuki T, Kuwahara J, Sugirura Y (1985) Copper bleomycin has no significant DNA cleavage activity. Biochemistry 24: 4719–4721
Takahashi K, Yoshioka O, Matsuda A, Umezawa H (1977) Intracellular reduction of the cupric ion of bleomycin copper complex and transfer of the cuprous ion to a cellular protein. J Antibiot 30: 861–869
Terasima T, Takabe Y, Katsumata T, Watanabe M, Umezawa H (1972) Effect of bleomycin on mammalian cell survival. J Natl Cancer Inst 49: 1093–1100
Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA (1979) Bleomycin induced pulmonary fibrosis in the rat. Am J Pathol 95: 117–130
Thrall RS, Barton RW, D'Amato DA, Sulavik SB (1982) Differential cellular analysis of bronchoalveolar lavage fluid obtained at various stages during the development of bleomycin induced pulmonary fibrosis in the rat. Am Rev Respir Dis 126: 488–492
Tom WW, Montgomery MR (1979) Disposition of the pulmonary toxin bleomycin. Drug Metab Dispos 7: 90–93
Uehara Y, Hori M, Umezawa H (1982) Specificity of transport of bleomycin and cobalt-bleomycin in L5178Y cells. Biochem Biophys Res Commun 104: 416–421
Uesugi S, Shida T, Ikehara M, Kobayashi Y, Kyogoku Y (1984) Identification of oligonucleotide fragments produced in a strand scission reaction of d(C-G-C-G-C-G) duplex by bleomycin. Nuc Acid Res 12: 1581–1592
Umezawa H, Maeda K, Takeuchi T, Okami Y (1966) New antibiotics, bleomycin A and B. Cancer 19: 201–209
Umezawa H, Ishizuka M, Maeda K, Takeuchi T (1967) Studies on bleomycin. Cancer 20: 891–895
Umezawa H, Ishizuka M, Hori S, Chimura H, Takeuchi T, Komai T (1968) The distribution of3H-bleomycin in mouse tissue. J Antibiot 21: 638–649
Umezawa H, Hori S, Sawa T, Yoshioka T, Takauchi T (1974) A bleomycin inactivating enzyme in mouse live. J Antibiot 27: 419–424
Vartio T, Zardi L, Balza E, Towin H, Vaheri A (1982) Monoclonal antibodies in analysis of cathepsin-G digested proteolytic fragments of human plasma fibronectin. J Immunol Methods 55: 309–318
Vartio T, Vaheri A, De-Petro G, Barlati S (1983) Fibronectin and its protealytic fragments. Potential as cancer markers. Invasion Metastasis 3[3]: 125–138
Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ (1981) Raynauds phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Int Med 95: 288–292
Wangensteen D, Yankovich R, Hoidal J, Neiwoehner D (1983) Bleomycin induced changes in pulmonary microvascular albumin permeability and extravascular albumin space. Am Rev Respir Dis 127: 204–208
Ward HE, Nicholson A, Berend N (1986a) Desferrioxamine infusion does not inhibit bleomycin induced lung damage in the rat. Am Rev Respir Dis 133: 317
Ward HE, Nicholson A, Berend N (1986b) Does systemic N-acetyl cystein (NAC) protect against bleomycin induced lung injury? Am Rev Respir Dis 133: A51
Wasserman SI (1980) The mast cell: its diversity of chemical mediators. Int J Dermathol 19: 7–17
Weatherhall DJ, Montell AE, Anderson WF, Badman DG (eds) (1981) Development of iron chelators for clinical use. Elsevier North Holland, New York, pp 3–12
Weizman SA, Graceffa P (1984) Asbestos catalyzes hydroxyl and superoxide radical generation from hydrogen peroxide. Arch Biochem Biophys 228: 373–376
White DA, Stover DE (1984) Severe bleomycin induced pneumonitis. Clinical features and response to corticosteroids. Chest 86: 723–728
Wilson JHU (1978) Pulmonary toxicity of antineoplastic drugs. Cancer Treat 62: 2008–2013
Woolley DE (1980) Human collagenase: comparative and immunolocalization studies in protein degradation in health and disease. Ciba Foundation Symposium 75: 69–82
Wu JC, Kozarich JW, Stubbe J (1985) Mechanism of bleomycin: evidence for a rate determining 4′-hydrogen abstraction from poly(dA-dU) associated with the formation of both free base and base propenal. Biochemistry 24: 7562–7568
Wu JC, Stubbe J, Kozarich JW (1985b) Mechanism of bleomycin: evidence of 4′-ketone formation in poly(dA-dU) associated exclusively with free base release. Biochemistry 24: 7569–7573
Yamamoto K, Hutchinson F (1984) The effect of bleomycin on DNA in escherichia coli K12 cells. Chem Biol Interact 51: 233–246
Yamauchi K, Basset P, Martinet Y, Crystal R (1987) Normal human alveolar macrophages express the gene coding for TGFβ, a protein with a capacity to express fibroblast growth. Am Rev Respir Dis 135: A66
Yamauchi K, Martinet Y, Basset P, Fells GA, Crystal RG (1988) High levels of transforming growth factor β are present in the epithelial lining of the normal human lower respiratory tract. Am Rev Respir Dis 137: 1360–1363
Yousem SA, Lifson JD, Colby TV (1985) Chemotherapy induced eosinophilic pneumonia. Chest 88: 103–106
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hay, J., Shahzeidi, S. & Laurent, G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 65, 81–94 (1991). https://doi.org/10.1007/BF02034932
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02034932